Effect of GLP-1 based therapies on diabetic dyslipidemia

Current Diabetes Reviews

Volumn 10, Issue 4, 2014, Pages 238-250

  Patel, Vishal J ^a,b   Joharapurkar, Amit A ^a   Shah, Gaurang B ^b   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Atherosclerosis; DPP 4 inhibitors; GLP 1; Lipid

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BODY WEIGHT; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; BLOOD; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLISM; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CHOLESTEROL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; RECEPTORS, GLUCAGON; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84924165085     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666140707092506     Document Type: Article

References (155)

1. Nikkila EA, Hormila P. Serum lipids and lipoproteins in insulintreated diabetes. Demonstration of increased high density lipoprotein concentrations. Diabetes 1978; 27(11): 1078-1086.
2. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3(2): 463-524.
3. Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Aguilar-Salinas CA. UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes. Curr Diabetes Rev 2010; 6(1): 1-8.
4. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005; 150(5): 859-870.
5. Yoshino G, Hirano T, Kazumi T. Dyslipidemia in diabetes mellitus. Diabetes Res Clin Pract 1996; 33(1): 1-14.
6. Brunzell JD, Hazzard WR, Motulsky AG, Bierman EL. Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities. Metabolism 1975; 24: 1115-1121.
7. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20(6): 876-913.
8. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34(9): 1411-1419.
9. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al.Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89(5): 1070-1077.
10. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004; 47(3): 357-366.
11. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128(2): 117-124.
12. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet 2002; 359(9309): 824-830.
13. Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 1988; 263(27): 13475-13478.
14. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142(2): 521-527.
15. Nauck MA, Wollschlager D, Werner J, et al.Effects of subcutaneous glucagon-like peptide 1 (GLP-17-36 amide]) in patients with NIDDM. Diabetologia 1996; 39(12): 1546-1553.
16. Schmidtler J, Dehne K, Allescher HD, et al.Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding. Am J Physiol 1994; 267(3 Pt 1): G423-G432.
17. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon- like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987; 84(10): 3434-3438.
18. Nauck MA, Niedereichholz U, Ettler R, et al.Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-E988.
19. Dardevet D, Moore MC, Neal D, et al.Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 2004; 287(1): E75-E81.
20. Naslund E, King N, Mansten S, et al.Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004; 91(3): 439-446.
21. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011; 27(3): 547-558.
22. Johnson KM, Edgerton DS, Rodewald T, et al.Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 2007; 293(4): E1085-E1091.
23. Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia 2014; 57(6): 1199-1203.
24. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60(4): 470-512.
25. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53 Suppl 3: S190-6.: S190-S196.
26. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009; %20; 150(2): 94-103.
27. Spellman CW. Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients. J Am Osteopath Assoc 2011; 111(2 Suppl 1): eS10-eS14.
28. Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF. Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans. Diabetes 2014; 63(7): 2394-2401.
29. Lambeir AM, Durinx C, Scharpe S, De MI. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40(3): 209-294.
30. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88(4): 1772-1779.
31. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebocontrolled clinical trials assessing the efficacy and safety of incretin- based medications in patients with type 2 diabetes. Pharmacology 2010; 86(1): 44-57.
32. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 2011; 34 Suppl 2: S264-71.: S264-S271.
33. Kolterman OG, Buse JB, Fineman MS, et al.Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88(7): 3082-3089.
34. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284(6): E1072-E1079.
35. Fineman MS, Bicsak TA, Shen LZ, et al.Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26(8): 2370-2377.
36. Juhl CB, Hollingdal M, Sturis J, et al.Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51(2): 424-429.
37. Degn KB, Juhl CB, Sturis J, et al.One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53(5): 1187-1194.
38. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon- like peptide 1 analog liraglutide (NN2211): a 12-week, double- blind, randomized, controlled trial. Diabetes Care 2004; 27(6): 1335-1342.
39. Biftu T, Sinha-Roy R, Chen P, et al.Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem 2014; 57(8): 3205-3212.
40. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163(9): 1077-1083.
41. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60(3): 473-485.
42. Speidel MT, Booyse FM, Abrams A, Moore MA, Chung BH. Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity. Thromb Res 1990; 58(3): 251-264.
43. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106(1): 83-97.
44. Wojdemann M, Wettergren A, Sternby B, et al.Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Dig Dis Sci 1998; 43(4): 799-805.
45. Hsieh J, Adeli K. Regulation of intestinal chylomicron production by glucagon-like peptides. Cardiovasc Hematol Disord Drug Targets 2012; 12(2): 92-97.
46. Parlevliet ET, Schroder-van der Elst JP, Corssmit EP, et al.CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 2009; 328(1): 240-248.
47. Qin X, Shen H, Liu M, et al.GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288(5): G943-G949.
48. Mitusuhashi T, Hibi K, konishi M, et al.Relation between plasma glucagon-like peptide-1 levels and tissue characteristics of the coronary plaque in non-diabetes patients with acute coronary syndrome. J Am Coll Cardiol 2014; 63(12_s): 1252-1282.
49. Mitusuhashi T, Hibi K, Osuka F, et al.Relation between plasma glucagon-like peptide-1 levels and tissue characteristics of the coronary plaque in non-diabetes patients with acute coronary syndrome. J Am Coll Cardiol 2012; 59(13S1): E2057.
50. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68(15): 2131-2162.
51. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2010; 299(2): E318-E324.
52. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995; 15(7): 963-971.
53. Sameer Ansar, Juraj Koska, PDR. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 2011; 10: 61.
54. Noda Y, Miyoshi T, Oe H, et al.Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in nondiabetic subjects: a preliminary report. Cardiovasc Diabetol 2013; 12: 8. doi: 10.1186/1475-2840-12-8.: 8-12.
55. Hsieh J, Longuet C, Baker CL, et al.The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53(3): 552-561.
56. Parlevliet ET, Wang Y, Geerling JJ, et al.GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. PLoS One 2012; 7(11): e49152.
57. Wang Y, Parlevliet ET, Geerling JJ, et al.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol 2014; 171(3): 723-734.
58. Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 2012; 696(1-3): 194-202.
59. Matikainen N, Manttari S, Schweizer A, et al.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49(9): 2049-2057.
60. Meier JJ, Gethmann A, Gotze O, et al.Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49(3): 452-458.
61. Klonoff DC, Buse JB, Nielsen LL, et al.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275-286.
62. Schwartz EA, Koska J, Mullin MP, et al.Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212(1): 217-222.
63. DeFronzo RA, Okerson T, Viswanathan P, et al.Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24(10): 2943-2952.
64. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(4): 366-373.
65. Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012; 32(6): 1513-1519.
66. Bansal S, Buring JE, Rifai N, et al.Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298(3): 309-316.
67. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012; 23(1): 56-61.
68. Farr S, Taher J, Adeli K. Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States. Cardiovasc Hematol Disord Drug Targets 2014.
69. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-165.
70. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43(1): 173-181.
71. Gupta NA, Mells J, Dunham RM, et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51(5): 1584-1592.
72. Piro S, Spadaro L, Russello M, et al.Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in nonalcoholic steatohepatitis. Nutr Metab Cardiovasc Dis 2008; 18(8): 545-552.
73. Laferrere B, Teixeira J, McGinty J, et al.Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93(7): 2479-2485.
74. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al.Glucagonlike peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31(9): 1285-1297.
75. Trevaskis JL, Griffin PS, Wittmer C, et al.Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302(8): G762-G772.
76. Ben Shlomo S, Zvibel I, Shnell M, et al.Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011; 54(6): 1214-1223.
77. Patel V, Joharapurkar A, Dhanesha N, et al.Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice. Pharmacol Rep 2013; 65(4): 927-936.
78. Patel V, Joharapurkar A, Gandhi T, et al.Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. J Diabetes 2013; 5(2): 163-171.
79. Patel V, Joharapurkar A, Dhanesha N, et al.Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in dietinduced obese C57 mice. Can J Physiol Pharmacol 2013; 91(12): 1009-1015.
80. Lee J, Hong SW, Chae SW, et al.Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012; 7(2): e31394.
81. Panjwani N, Mulvihill EE, Longuet C, et al.GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154(1): 127-139.
82. Shirakawa J, Fujii H, Ohnuma K, et al.Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60(4): 1246-1257.
83. Jung YA, Choi YK, Jung GS, et al.Sitagliptin attenuates methionine/ choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract 2014; (14): 10.
84. Mells JE, Fu PP, Sharma S, et al.Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012; 302(2): G225-G235.
85. Mells JE, Anania FA. The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis 2013; 33(4): 343-357.
86. Tushuizen ME, Bunck MC, Pouwels PJ, et al.Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26(8): 1015-1017.
87. Cuthbertson DJ, Irwin A, Gardner CJ, et al.Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012; 7(12): e50117.
88. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263(3): 256-273.
89. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006; 17(3): 247-257.
90. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51(23): 2199-2211.
91. van Dam MJ, de Groot E, Clee SM, et al.Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359(9300): 37-42.
92. Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis 2003; 170(1): 31-38.
93. Chirinos JA, Zambrano JP, Chakko S, et al.Ability of serum to decrease cellular acylCoA: cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation 2005; 112(16): 2446-2453.
94. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113(21): 2548-2555.
95. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007; 100: 32-40.
96. Rothblat GH, Llera-Moya M, Atger V, et al.Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40(5): 781-796.
97. Pajunen P, Syvanne M, Castro G, Nieminen MS, Taskinen MR. Cholesterol efflux capacity in vitro predicts the severity and extent of coronary artery disease in patients with and without type 2 diabetes. Scand Cardiovasc J 2001; 35(2): 96-100.
98. Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I: A-II particles and phospholipid transfer protein. Atherosclerosis 1996; %20; 127(2): 245-253.
99. Curtiss LK, Witztum JL. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985; 34(5): 452-461.
100. Passarelli M, Shimabukuro AF, Catanozi S, et al.Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus. Clin Chim Acta 2000; 301(1-2): 119-134.
101. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33(12): 1051-1069.
102. de Boer JF, Annema W, Schreurs M, et al.Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. J Lipid Res 2012; 53(3): 348-357.
103. Navab M, Hama SY, Cooke CJ, et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41(9): 1481-1494.
104. Persegol L, Foissac M, Lagrost L, et al.HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007; 50(11): 2384-2387.
105. Irwin N, McClean PL, Hunter K, Flatt PR. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. Diabetes Obes Metab 2009; 11(6): 603-610.
106. Blonde L, Klein EJ, Han J, et al.Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8(4): 436-447.
107. Vanderweele DA, Geiselman PJ, Novin D. Pancreatic glucagon, food deprivation and feeding in intact and vagotomized rabbits. Physiol Behav 1979; 23(1): 155-158.
108. Chehade JM, Alcalde R, Naem E, et al.Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells. Metabolism 2012.
109. Ban K, Noyan-Ashraf MH, Hoefer J, et al.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and - independent pathways. Circulation 2008; 117(18): 2340-2350.
110. Nagashima M, Watanabe T, Terasaki M, et al.Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011; 54(10): 2649-2659.
111. Tashiro Y, Sato K, Watanabe T, et al.A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014; 54: 19-26. doi: 10.1016/j.peptides.2013.12.015. Epub; %2014 Jan 10.: 19-26.
112. Dai Y, Dai D, Wang X, et al.GLP-1 Agonists Inhibit Ox-LDL Uptake in Macrophages by Activating Protein Kinase A. J Cardiovasc Pharmacol 2014.
113. Shlomo SB, Zvibel I, Rabinowich L, et al.Dipeptidyl Peptidase 4- Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. Dig Dis Sci 2012.
114. Ben Shlomo S, Zvibel I, Rabinowich L, et al.Erratum to: Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. Dig Dis Sci 2012.
115. Rafferty EP, Wylie AR, Hand KH, et al.Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. Biol Chem 2011; 392(6): 539-546.
116. Liu HY, Chung CY, Yang WC, et al.Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice. J Vet Sci 2012; 13(3): 245-252.
117. Montrose-Rafizadeh C, Yang H, Wang Y, et al.Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 1997; 172(3): 275-283.
118. Ruiz-Grande C, Alarcon C, Merida E, Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 1992; 13(1): 13-16.
119. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001; 33(2): 73-77.
120. Yang J, Ren J, Song J, et al.Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int J Mol Med 2013; 31(6): 1429-1435.
121. Zhu H, Weng Z, Lin C, Ma J, Zhong X. Glucagon-like peptide-1 regulates lipometabolism by down-regulating adipose triglyceride lipase in 3T3-L1 adipocytes]. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33(10): 1499-1503.
122. Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7- 36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993; 77(6): 1654-1657.
123. Bertin E, Arner P, Bolinder J, Hagstrom-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 2001; 86(3): 1229-1234.
124. Sancho V, Trigo MV, Martin-Duce A, et al.Effect of GLP-1 on Dglucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 2006; 17(6): 1133-1137.
125. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976; 99(3): 780-785.
126. Cybulsky MI, Iiyama K, Li H, et al.A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107(10): 1255-1262.
127. Mogi C, Tobo M, Tomura H, et al.Involvement of proton-sensing TDAG8 in extracellular acidification-induced inhibition of proinflammatory cytokine production in peritoneal macrophages. J Immunol 2009; 182(5): 3243-3251.
128. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon- like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun 2012; 425(2): 304-308.
129. Arakawa M, Mita T, Azuma K, et al.Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59(4): 1030-1037.
130. Ma GF, Chen S, Yin L, Gao XD, Yao WB. Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-kappaB pathway. Acta Pharmacol Sin 2014; 35(2): 195-202.
131. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10(4): 353-360.
132. Burgmaier M, Liberman A, Mollmann J, et al.Glucagon-like peptide- 1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28- 37) stabilize atherosclerotic lesions in apoe(-)/(-) mice. Atherosclerosis 2013; 231(2): 427-435.
133. Vittone F, Liberman A, Vasic D, et al.Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012; 55(8): 2267-2275.
134. Terasaki M, Nagashima M, Nohtomi K, et al.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013; 8(8): e70933.
135. Piotrowski K, Becker M, Zugwurst J, et al.Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol 2013; 12: 117. doi: 10.1186/1475-2840-12-117.: 117-12.
136. Nystrom T, Gutniak MK, Zhang Q, et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287(6): E1209-E1215.
137. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010; 33(5): 1028-1030.
138. Basu A, Charkoudian N, Schrage W, et al.Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293(5): E1289-E1295.
139. Katakami N, Mita T, Yoshii H, et al.Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). J Atheroscler Thromb 2013; 20(12): 893-902.
140. Irace C, De Luca S, Shehaj E, et al.Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013; 10(1): 72-77.
141. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34(9): 2072-2077.
142. Noda Y, Miyoshi T, Oe H, et al.Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in nondiabetic subjects: a preliminary report. Cardiovasc Diabetol 2013; 12: 8. doi: 10.1186/1475-2840-12-8.: 8-12.
143. Kubota Y, Miyamoto M, Takagi G, et al.The dipeptidyl peptidase- 4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 12 A.D; 12: 1364-1370.
144. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115(8): 477-482.
145. Lamarche B, St Pierre AC, Ruel IL, et al.A prospective, population- based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001; 17(8): 859-865.
146. Scheffer PG, Tushuizen ME, Vermue HP, et al.Effect of three consecutive meals on the physicochemical properties of HDL and LDL in individuals with the metabolic syndrome and patients with type 2 diabetes. Eur J Clin Nutr 2011; 65(11): 1242-1249.
147. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009; 202(1): 162-168.
148. Chancharme L, Therond P, Nigon F, et al.Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler Thromb Vasc Biol 1999; 19(3): 810-820.
149. Rizzo M, Berneis K, Koulouris S, et al.Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? Int J Clin Pract 2010; 64(12): 1632-1642.
150. Mikhailidis DP, Elisaf M, Rizzo M, et al."European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-571.
151. Sevanian A, Hwang J, Hodis H, et al.Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16(6): 784-793.
152. Nauck MA, Duran S, Kim D, et al.A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50(2): 259-267.
153. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359(11): 1092-1095.
154. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10(2): 73-84.
155. Goto H, Nomiyama T, Mita T, et al.Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011; 405(1): 79-84.